Replies to post #22 on TBG Diagnostics Ltd fka TDLAF

[busker]

Posted by Rawnoc: 'Brave'

Agree that all developing biotech companies are in the high risk category.

Clearly, a good deal of company research is required before taking a position.

But why is it ‘brave’ to take a position in PGLA ??

Find me another developing biotech, which are in a similar strong position as Progen is.

~$100MM in cash or cash equivalent investments/deposits.
Only 59.4MM stock on issue
Only ~3MM options (listed and unlisted)
Very low burn rate. (headcount is less than 50)
Five (5) P2 trials in progress or completed.
Extensive pipeline.
Commencement of P3 (HCC liver) before end 2007
Enough cash to see PI-88 to commercial stage.
FDA Fast track.
P3 CRO appointed
SPA negotiations with FDA.
The commencement of P3 will see a fast enrollment of patients in ~12 countries.

July 2007 Corporate Facts sheet
http://www.progen-pharma.com/in/July07.pdf

July 2007 Progress presentation
http://www.progen-pharma.com/prs/PGL%20Progress%20Update%2011%20July%202007.pdf

Stay tuned for the latest developments from the CEO on Thursday;

Justus Homburg, Chief Executive Officer, will present at the Thomas Weisel Partners Healthcare Conference at The Four Seasons Hotel in Boston, MA on Thursday, 6 September 2007 at 9:10 AM EDT (Thursday, 6 September, 2007 at 11:10 PM Brisbane EST)

The audio presentation will be webcast live, and can be accessed on the Company’s website at www.progen-pharma.com.